ライフサイエンスコーパス: inosine

1 , A = adenine, T= thymine, C = cytosine, I = inosine).

2 hodiester bond 3' to a deaminated adenosine (inosine).

3 2B antagonist PSB603 prevented the effect of inosine.

4 s to restore levels of the purine metabolite inosine.

5 adenosine 34 of tRNA(Opt)AUG is converted to inosine.

6 ages at the second phosphodiester bond 3' to inosine.

7 from cells and catabolized by deamination to inosine.

8 ine deaminase (ADA) catabolizes adenosine to inosine.

9 0% of adenosine residues may be converted to inosine.

10 display increased circulating bile acids and inosine.

11 anslation are independent of the presence of inosine.

12 ystemic treatment with the purine nucleoside inosine.

13 cules are post-transcriptionally modified to inosines.

14 Rs) deaminate adenosines in dsRNA to produce inosines.

15 Inosine (1 mM) delivered intravesically to SCI rats duri

16 In isolated tissue assays, inosine (1 mM) significantly decreased the amplitude of

17 Treatment with inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI)

18 enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deox

19 ing a third universal bacterial primer pair (inosine-341f and 1492r).

20 e ribose (cADPR) analogs based on the cyclic inosine 5'-diphosphate ribose (cIDPR) template were synt

21 tal synthesis, analogues based on the cyclic inosine 5'-diphosphate ribose (cIDPR) template were synt

22 In Jurkat T cells, unlike the parent cyclic inosine 5'-diphosphoribose N1-cIDPR 2, 6-thio N1-cIDPR a

23 yclic product 6-thio N1-cIDPR (6-thio cyclic inosine 5'-diphosphoribose, 3), although the correspondi

24 When inosine 5'-monophosphate (IMP), a ribonucleotide that po

25 po") form and in complex with its substrate, inosine 5'-monophosphate (IMP), and product, xanthosine

26 of a combination of monosodium glutamate and inosine 5'-monophosphate (MSG/IMP) provided either alone

27 preload with added monosodium glutamate and inosine 5'-monophosphate (MSG/IMP+) or without added mon

28 +) or without added monosodium glutamate and inosine 5'-monophosphate (MSG/IMP-) were consumed on 4 n

29 Inosine 5'-monophosphate acts synergistically with MSG w

30 Cryptosporidium inosine 5'-monophosphate dehydrogenase (CpIMPDH) has eme

31 Inosine 5'-monophosphate dehydrogenase (IMP dehydrogenas

32 nosine 5'-monophosphate reductase (GMPR) and inosine 5'-monophosphate dehydrogenase (IMPDH) are purin

33 Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes

34 sine in a streamlined pathway that relies on inosine 5'-monophosphate dehydrogenase (IMPDH).

35 Since the introduction of the inosine 5'-monophosphate dehydrogenase inhibitors (mycop

36 gly, particularly in direct comparisons with inosine 5'-monophosphate dehydrogenase inhibitors.

37 conversion of phosphoribosylpyrophosphate to inosine 5'-monophosphate.

38 examples in nucleotide biosynthesis pathways-inosine-5'-monophosphate (IMP) dehydrogenase and cytosin

39 codynamic measurements require evaluation of inosine-5'-monophosphate dehydrogenase (IMPDH) activity,

40 revealed that the parasite relies solely on inosine-5'-monophosphate dehydrogenase (IMPDH) for the b

41 Inosine-5'-monophosphate dehydrogenase (IMPDH) has been

42 Inosine-5'-monophosphate dehydrogenase (IMPDH) is an ess

43 We report the in vivo regulation of Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) in the

44 e] 1 alpha subcomplex subunit 9 (NDUFA9) and inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) as ace

45 , p38alpha signaling increases expression of inosine-5'-monophosphate dehydrogenase 2 in HSPCs, leadi

46 These results suggest that MPA inhibits inosine-5'-monophosphate dehydrogenase activity in eryth

47 -7 cells treated with MPA showed a decreased inosine-5'-monophosphate dehydrogenase activity.

48 KCl, NH(4)Cl, sucrose, monosodium glutamate/inosine-5'-monophosphate, citric acid, quinine, or artif

49 RNA editing of adenosine to inosine (A to I) is catalyzed by ADAR1 and dramatically

50 or paraspeckles, as well as for adenosine to inosine (A to I) RNA editing of Ctn RNA in muscle cells.

51 Altered levels of adenosine-to-inosine (A-to-I) editing are observed in several disease

52 we profiled global patterns of adenosine-to-inosine (A-to-I) editing in a large cohort of postmortem

53 regions of brain showed higher adenosine to inosine (A-to-I) editing in mature miRNAs.

54 Adenosine-to-inosine (A-to-I) editing is a highly prevalent posttrans

55 Adenosine-to-inosine (A-to-I) editing is a site-selective post-transc

56 Adenosine-to-inosine (A-to-I) editing of dsRNA by ADAR proteins is a

57 pts that have been subjected to adenosine-to-inosine (A-to-I) editing.

58 seed" sequence modifications by adenosine-to-inosine (A-to-I) editing.

59 ly, we developed a programmable adenosine-to-inosine (A-to-I) RNA editing approach by fusing catalyti

60 Genome Atlas and identified 19 adenosine-to-inosine (A-to-I) RNA editing hotspots.

61 Adenosine to Inosine (A-to-I) RNA editing is a co- or post-transcript

62 Adenosine-to-inosine (A-to-I) RNA editing is a conserved post-transcr

63 Adenosine-to-inosine (A-to-I) RNA editing is a neurodevelopmentally r

64 Adenosine-to-Inosine (A-to-I) RNA editing is a post-transcriptional m

65 Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transc

66 es in neural activity can alter adenosine-to-inosine (A-to-I) RNA editing, a post-transcriptional sit

67 Adenosine-to-inosine (A-to-I) RNA editing, catalysed by ADAR enzymes

68 Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by ADAR enzymes,

69 Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by Adenosine DeA

70 Adenosine-to-inosine (A-to-I) RNA editing, in which genomically encod

71 atalyze the editing of adenosine residues to inosine (A-to-I) within RNA sequences, mostly in the int

72 s the conversion of adenosine nucleosides to inosine (A-to-I), mediated by the ADAR family of enzymes

73 e type of RNA editing converts adenosines to inosines (A-->I editing) in double-stranded RNA (dsRNA)

74 newly available thermodynamic parameters for inosine, a modified adenine base with an universal base

75 Inosine, a naturally occurring purine nucleoside, has be

76 Following unilateral stroke in rats, inosine, a naturally occurring purine nucleoside, stimul

77 Biochemically, they convert adenosine to inosine, a nucleotide that is read as guanosine during t

78 These results reveal that the microbiota-inosine-A2A receptor axis might represent a potential av

79 ore, purified axoplasm exhibits adenosine-to-inosine activity and can specifically edit adenosines in

80 These findings demonstrate that inosine acts via an A2B receptor-mediated pathway that i

81 in which adenosine residues are converted to inosine (adenosine-to-inosine editing).

82 ealed that the adoption of a spatially broad inosine-adenosine base pair at the wobble position of th

83 levels were associated with higher levels of inosine, an adenosine surrogate, and of cyclic adenosine

84 ns of tRNA(Arg1) and tRNA(Arg2) both contain inosine and 2-methyladenosine modifications at positions

85 AppN caps, we show that aprataxin hydrolyzes inosine and 6-O-methylguanosine caps, but is not adept a

86 the irreversible deamination of adenosine to inosine and ammonia.

87 ously described trimeric PNP that can cleave inosine and guanosine only and a second, novel PNP (Ado-

88 While Ado was the preferred substrate, inosine and guanosine were also cleaved, with 43% and 32

89 e generated in various ways involving either inosine and hypoxanthine or guanosine and xanthosine as

90 aliana) mainly generates xanthosine, but not inosine and hypoxanthine, and that xanthosine is derived

91 Nucleosides and nucleotides (e.g., inosine and inosine monophosphate) were also found to be

92 lysis of B. anthracis spores germinated with inosine and L-alanine, we previously determined kinetic

93 Concentrations of inosine and leucine were significantly different between

94 which were also required for the efficacy of inosine and of L. reuteri in vivo.

95 se constituent nucleosides are adenosine and inosine and that vary by ribose substitution, internucle

96 d we confirm the deamination of adenosine to inosine and the formation of tRNAValIACin vitro by ON-MS

97 preferentially targets the purine ribosides inosine and xanthosine, while the other is more active t

98 nd, novel PNP (Ado-PNP) that can cleave Ado, inosine, and guanosine.

99 series of imides, azinones (including AZT), inosines, and cyclic sulfonamides has been examined.

100 lites, including xanthine, hypoxanthine, and inosine are elevated.

101 oward which the corresponding sugar-modified inosines are compared.

102 advancing to more definitive development of inosine as a potential disease-modifying therapy for PD.

103 sponsible for the conversion of adenosine to inosine at specific locations in cellular RNAs.

104 R2 catalyses the deamination of adenosine to inosine at the GluR2 Q/R site in the pre-mRNA encoding t

105 The formation of inosine at the wobble position of eukaryotic tRNAs is an

106 Inosine augments neurons' intrinsic growth potential by

107 RNA, specific adenosines can be converted to inosines, biological mimics for guanosine.

108 the recombinant protein and cleaves RNA with inosine but not DNA.

109 the deamination of particular adenosines to inosine by adenosine deaminases acting on RNA (ADARs).

110 an cells as HAPR is primarily metabolized to inosine by direct dehydroxylamination catalyzed by adeno

111 her nucleophiles also worked (e.g., MocVinyl-inosines can be cleaved with succinimide anion).

112 Because ADA converts adenosine to inosine, cells lacking this enzyme might be subject to p

113 Escherichia coli Endonuclease V (eEndoV), an inosine-cleaving enzyme, can be repurposed to bind and i

114 teral stroke in the rat forelimb motor area, inosine combined with NEP1-40, a Nogo receptor antagonis

115 ated using 5'-labeled and internally-labeled inosine-containing DNA and a H214D mutant that is defect

116 ndoV-seq utilizes Endonuclease V to nick the inosine-containing DNA strand of genomic DNA deaminated

117 ologs from bacteria to mouse in complex with inosine-containing DNA/RNA hybrid or double-stranded RNA

118 RNAs may undergo hyper-editing, the role for inosine-containing hyper-edited double-stranded RNA in c

119 lism, and purine metabolism [(hypo) xanthine/inosine-containing pathways].

120 stimulates hEndoV activity and affinity for inosine-containing RNA.

121 lated in cells to avoid aberrant cleavage of inosine-containing transcripts.

122 build-up of its degradation products, mainly inosine (control: 13.25; urchins held in air: 82.87 and

123 Adenosine-to-inosine conversion (A-to-I editing), a posttranscription

124 DARs) are enzymes that catalyze adenosine to inosine conversion in dsRNA, a common form of RNA editin

125 active Cas13 (dCas13) to direct adenosine-to-inosine deaminase activity by ADAR2 (adenosine deaminase

126 rocytes and fibroblasts have an adenosine to inosine deamination defect caused by reduction of adenos

127 range of the chemosensor was 0.5-50 muM with inosine detectability of 0.62 muM.

128 The imprinting factor for inosine, determined from piezomicrogravimetric experimen

129 o participant developed gout and 3 receiving inosine developed symptomatic urolithiasis.

130 Mean levels of guanosine, inosine, dGuo, and dIno were 4.4, 133.3, 3.6, and 3.8 mu

131 Inosine did not affect CST sprouting in the lumbar spina

132 ing to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deoxy-guanosine (dGuo)

133 Inosine, dIno, guanosine, and dGuo were tested by using

134 y deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited iso

135 directly visualize and quantify adenosine-to-inosine-edited transcripts in situ.

136 ty to the tandem dsRBDs from an adenosine-to-inosine editing enzyme, ADAR2 in complex with a substrat

137 A adenosine deaminases catalyze adenosine-to-inosine editing in position 34 of several cytosolic tRNA

138 We also describe how adenosine-to-inosine editing influences SINE function and how ongoing

139 Adenosine-to-inosine editing is one of the most frequent post-transcr

140 Thus, adenosine-to-inosine editing may also represent an important defense

141 We find widespread loss of adenosine-to-inosine editing of Alu RNAs in MS.

142 RATIONALE: Adenosine-to-inosine editing of microRNAs has the potential to cause

143 on RNA (ADAR1), responsible for adenosine-to-inosine editing of RNA, is required for regulating the d

144 on, we identified and validated adenosine-to-inosine editing of the miR487b seed sequence.

145 angiomiR miR487b is subject to adenosine-to-inosine editing or 2'-O-ribose-methylation during neovas

146 idues are converted to inosine (adenosine-to-inosine editing).

147 ever, has been shown to inhibit adenosine-to-inosine editing.

148 d, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and fol

149 le-helical DNA molecules substituting either inosine for guanosine or 2,6-diaminopurine for adenine.

150 ty, methoxyamine capping of the Ap aldehyde, inosine-for-guanine replacement, hydroxyl radical footpr

151 quential replacement of canonical bases with inosine greatly simplifies the problem and defines a new

152 rum urate rose by 2.3 and 3.0 mg/dL in the 2 inosine groups (P < .001 for each) vs placebo, and cereb

153 spinal fluid urate level was greater in both inosine groups (P = .006 and <.001, respectively).

154 , occurred at the same or lower rates in the inosine groups relative to placebo.

155 he flanking purine, decreasing in the order: inosine > adenine > guanine > deazaguanine.

156 hat binding of the second messenger ppGpp to inosine-guanosine kinase (Gsk) in E. coli modulates the

157 basis of inhibition for one target, Gsk, the inosine-guanosine kinase.

158 Editing of adenosine (A) to inosine (I) at the first anticodon position in tRNA is c

159 ct on RNA (ADARs) carry out adenosine (A) to inosine (I) editing reactions with a known requirement f

160 the deamination of adenosine (A) to produce inosine (I) in double-stranded (ds) RNA structures, a pr

161 y C6 deamination of adenosine (A) to produce inosine (I) in double-stranded (ds) RNA.

162 C-6 deamination of adenosine (A) to produce inosine (I) in RNA substrates with a double-stranded cha

163 e Acting on RNA (ADAR2) that deaminates A to inosine (I) residues that are subsequently translated as

164 pression both by catalyzing adenosine (A) to inosine (I) RNA editing and binding to regulatory elemen

165 Adenosine (A) to inosine (I) RNA editing contributes to transcript divers

166 C-6 deamination of adenosine (A) to produce inosine (I), which behaves as guanine (G), thereby alter

167 me ADAR chemically modifies adenosine (A) to inosine (I), which is interpreted by the ribosome as a g

168 s the base adenosine (A) in RNA molecules to inosine (I), which is recognized as guanine (G) in trans

169 A(Arg1,2) are also modified at positions 34 (inosine, I(34)) and 37 (2-methyladenosine, m(2)A(37)).

170 Inosine (IC50 = 3.7 microM) and guanosine (IC50 = 21.3 m

171 ctability compares well to the levels of the inosine in body fluids which are in the range 0-2.9 micr

172 ng only ADAT3-V144M exhibit decreased wobble inosine in certain tRNAs.

173 e the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) and thereby poten

174 NA editing enzymes that convert adenosine to inosine in double-stranded RNA (dsRNA).

175 s acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA.

176 ADARs) are enzymes that convert adenosine to inosine in duplex RNA, a modification that exhibits a mu

177 genomically encoded adenosine is changed to inosine in RNA, is catalyzed by adenosine deaminase acti

178 age and thus enable high affinity capture of inosine in RNA.

179 th and inefficient editing from adenosine to inosine in six nucleus-encoded tRNA species.

180 miR-4459 and hsa-miR-135a-3p expression with inosine in the vein tissue, while miR-216a-5p, conversel

181 acting on RNA (ADARs) convert adenosines to inosines in double-stranded RNA (dsRNA) in animals.

182 V (EndoV) is an enzyme with specificity for inosines in nucleic acids.

183 inding proteins that deaminate adenosines to inosines in pre-mRNA hairpins and also exert editing-ind

184 RNA editing converts single adenosines into inosines in pre-mRNA.

185 n RNAs (ADARs) convert adenosine residues to inosines in primary microRNA (pri-miRNA) transcripts to

186 As inosines in RNA are highly abundant, hEndoV activity is

187 f the conversion of specific adenosines into inosines in RNA molecules.

188 A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylate

189 hosphate (AMP), inosine monophosphate (IMP), inosine (Ino) and hypoxanthine (Hx), in fish tissue, bas

190 toring molecules such as adenosine (Ado) and inosine (Ino) in the central nervous system has enabled

191 We also measured ADO and inosine (INO) levels in tissues by mass spectrometry.

192 tic acid, alanine, methionine, fumaric acid, inosine, inosine monophosphate, creatine, betaine, carno

193 Conversion of adenosine to inosine is a frequent type of RNA editing, but important

194 Inosine is now in clinical trials for other indications,

195 Since inosine is recognized during translation as guanosine, t

196 ies and repurposed drugs, such as nilotinib, inosine, isradipine, iron chelators and anti-inflammator

197 Feeding inosine itself prolonged life and inhibited multiorgan i

198 Accordingly, inosine levels are highest in human pluripotent embryoni

199 Elevated plasma xanthine and inosine levels were associated with a higher T2D risk in

200 ylcholine (18:2), uric acid, citrulline, and inosine levels, which are generally low in pancreatic ca

201 e metabolism, most notably by an increase in inosine levels.

202 monophosphate) and nucleoside (adenosine and inosine) levels were quantified by high-performance liqu

203 es, bulge loops, CNG repeats, dangling ends, inosines, locked nucleic acids, 2-hydroxyadenines and az

204 equilibrating Michaelis complexes (PNP.PO(4).inosine <--> PNP.Hx.R-1-P) and inhibited complexes (PNP.

205 Our results suggest that inosine may improve functional outcome after TBI.

206 ctic measure during nitroprusside treatment, inosine may serve as a biomarker of cyanide exposure, an

207 r ADAT2-dependent folding of ADAT3 in wobble inosine modification and indicate that proper formation

208 mmune sensing, and functions of adenosine to inosine modifications in retroviral life cycles.

209 In contrast, the inosine monophasphate dehydrogenase dedicated to guanosi

210 at PfISN1 catalyzes the dephosphorylation of inosine monophosphate (IMP) and is allosterically activa

211 Inosine monophosphate (IMP) dehydrogenase 2 (IMPDH2) is

212 sphate (ADP), adenosine monophosphate (AMP), inosine monophosphate (IMP), inosine (Ino) and hypoxanth

213 deregulated serum acylcarnitines, including inosine monophosphate and adenosine monophosphate (purin

214 nucleotide cycle (PNC) between adenosine and inosine monophosphate and adenylosuccinate, which consum

215 le in the formation of the key intermediates inosine monophosphate and AMP involved in the synthesis

216 carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC) and thereby

217 -4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase, Steps 9 and 10), w

218 Interindividual variation in inosine monophosphate dehydrogenase (IMPDH) enzyme activ

219 The guanine nucleotide biosynthetic enzyme inosine monophosphate dehydrogenase (IMPDH) forms octame

220 MPA is a potent inosine monophosphate dehydrogenase (IMPDH) inhibitor bu

221 Inosine monophosphate dehydrogenase (IMPDH) mediates the

222 The inosine monophosphate dehydrogenase (IMPDH) protein GuaB

223 We recently reported that Inosine Monophosphate Dehydrogenase (IMPDH), a rate-limi

224 tem and hypoxanthine require the activity of inosine monophosphate dehydrogenase (IMPDH), the rate-li

225 reductase-thymidylate synthase (DHFR-TS) and inosine monophosphate dehydrogenase (IMPDH).

226 Antibodies to inosine monophosphate dehydrogenase 2 (IMPDH2) and cytid

227 ANKRD9 facilitates degradation of inosine monophosphate dehydrogenase 2 (IMPDH2), the rate

228 ere-associated protein E (Cenpe), Gpr49, and inosine monophosphate dehydrogenase type II] with previo

229 The highest concentration of inosine monophosphate was achieved in freshly prepared g

230 al steps from phosphoribosylpyrophosphate to inosine monophosphate were recently shown to associate i

231 cleosides and nucleotides (e.g., inosine and inosine monophosphate) were also found to be transformed

232 nce of several umami (uridine monophosphate, inosine monophosphate, adenosine, and guanosine) and kok

233 alanine, methionine, fumaric acid, inosine, inosine monophosphate, creatine, betaine, carnosine and

234 inamide adenine dinucleotide (NAD)-mimicking inosine monophsophate dehydrogenase (IMPDH) inhibitors h

235 ntral intermediate in purine catabolism, the inosine nucleobase hypoxanthine is also one of the most

236 t of BtO(-) from the O(6)-(benzotriazol-1-yl)inosine nucleosides by azide anion.

237 resent study, we investigated the effects of inosine on motor and cognitive deficits, CST sprouting,

238 Mechanistically, the inhibition of inosine on the differentiation of Th1 and Th2 cells in v

239 undamaged cortex well beyond those seen with inosine or EE alone.

240 red by the related purine metabolite 5'-AMP, inosine, or hypoxanthine.

241 adenosine kinase inhibition (with A134974), inosine, or uridine also required ARs, as each was aboli

242 to demonstrate EndoVIPER-seq (Endonuclease V inosine precipitation enrichment sequencing) as a facile

243 Inosine recognition is conserved, but changes in several

244 al sensor for selective determination of the inosine, renal disfunction biomarker, was devised and pr

245 idine or adenosine nucleotides to uridine or inosine, respectively, in mRNAs.

246 Adenosine to inosine RNA editing catalyzed by ADAR enzymes is common

247 Informational recoding by adenosine-to-inosine RNA editing diversifies neuronal proteomes by ch

248 and a propensity for increased adenosine-to-inosine RNA editing during CML progression.

249 Since adenosine-to-inosine RNA editing has recently emerged as a driver of

250 idence has suggested a role for adenosine-to-inosine RNA editing in carcinogenesis.

251 Adenosine-to-inosine RNA editing in transcripts encoding the voltage-

252 While adenosine-to-inosine RNA editing is consistently deregulated in cance

253 Post-transcriptional adenosine-to-inosine RNA editing mediated by adenosine deaminase acti

254 Adenosine-to-inosine RNA editing, a fundamental RNA modification, is

255 0% of human transcripts undergo adenosine to inosine RNA editing, and editing is required for normal

256 acting on RNA (ADAR)-dependent adenosine-to-inosine RNA editing.

257 ; (3) enhances the frequency of adenosine-to-inosine RNA editing; and (4) dramatically increases the

258 ochemically interacted with the adenosine-to-inosine RNA-editing enzyme dADAR.

259 ingly deprotonated forms of hypoxanthine and inosine show drastic differences, where the latter remai

260 The dependence on an inosine site and the exonuclease nature of the 3'-exonuc

261 editing that converts adenosine residues to inosine specifically in double-stranded RNAs.

262 olecular inversion probes were designed with inosine strategically positioned to complement suspected

263 A guanine-to-inosine substitution, which selectively knocks out a Wat

264 h G:U wobble pairs, and splints with G to I (Inosine) substitutions all allowed for the efficient ass

265 abolically the adenosine deaminase defect by inosine supplementation was beneficial bioenergetically

266 Inosine supplementation, in combination with modulation

267 ic acid substituents, in the presence of the inosine template and a thiophene cross-linker.

268 For that purpose, inosine-templated molecularly imprinted polymer (MIP) fi

269 domized to 1 of 3 treatment arms: placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or mode

270 pyrimidine-2,4-diones (AZT derivatives), or inosines to the electron-deficient triple bonds of methy

271 condary analyses demonstrated nonfutility of inosine treatment for slowing disability.

272 Genetic variation of inosine triphosphatase (ITPA) causing an accumulation of

273 Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triph

274 Inosine triphosphatase (ITPA) variants causing ITPase de

275 e inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect again

276 C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to

277 t enzymes involved in the purine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, pu

278 hosphatase (ITPA) causing an accumulation of inosine triphosphate (ITP) has been shown to protect pat

279 single-nucleotide polymorphism (SNP) in the inosine triphosphate (ITPA) gene and hemolytic anemia in

280 Pauses triggered by inosine triphosphate misincorporation led to backtrackin

281 dy evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA

282 loss of function mutations in ITPA, encoding inosine triphosphate pyrophosphatase (ITPase).

283 ize translation of codons that depend on the inosine tRNA modification in the anticodon wobble positi

284 For example, an A-U, inosine*U and pseudouridine*A pair each form two hydroge

285 as to investigate the mechanism of action of inosine underlying improvement of NDO.

286 milar functional improvements were seen when inosine was combined with environmental enrichment (EE).

287 Inosine was generally safe, tolerable, and effective in

288 The effect of inosine was mimicked by the adenosine receptor agonist N

289 The inhibition of SA by inosine was not observed in the presence of the BK antag

290 In addition, inosine was shown as a potential independent diagnostic

291 utamate, taurine, myo-inositol, creatine and inosine were present in aqueous extracts and phosphatidy

292 xcitation of hypoxanthine and its nucleoside inosine were studied by femtosecond fluorescence up-conv

293 t deprotonation sites in hypoxanthine versus inosine, which gives rise to significantly different res

294 the C-6 deamination of adenosine to produce inosine, which is recognized as guanosine, a process kno

295 The deamination of adenine yields inosine, which is treated as guanine by polymerases, but

296 Higher selectivity for inosine with respect to common interferents was also ach

297 levels of Ca(2+) instead promote binding of inosine without cleavage and thus enable high affinity c

298 The present study investigated whether inosine would complement the effects of treatments that

299 lB family transcriptional antiterminator, an inosine/xanthosine triphosphatase, GidA, a methyl-accept

300 Replacing guanosine with more weakly pairing inosine yielded an RNA that folded rapidly without a fac